{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:08:51Z","timestamp":1787868531111,"version":"build-2784847793"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.vaccine.2024.01.034","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T15:42:48Z","timestamp":1705938168000},"page":"1122-1135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates"],"prefix":"10.1016","volume":"42","author":[{"given":"Ranajit","family":"Pal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2872-8621","authenticated-orcid":false,"given":"Yoshikazu","family":"Honda-Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Wattay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesica","family":"Caple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Navarrete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-5245","authenticated-orcid":false,"given":"Nikolai","family":"Petrovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.01.034_b0005","unstructured":"World Health Organisation. Weekly operational update on COVID-19 -20 September 2021. 2021. p. 1-16."},{"key":"10.1016\/j.vaccine.2024.01.034_b0010","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1017\/S0950268823000420","article-title":"Comparative transmission of SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants and the impact of vaccination: national cohort study, England","volume":"151","author":"Allen","year":"2023","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2024.01.034_b0015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cmi.2022.09.001","article-title":"Evaluating the efficacy and safety of SpikoGen(R), an advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial","volume":"29","author":"Tabarsi","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2024.01.034_b0020","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.936523","article-title":"Editorial: First approval of the protein-based adjuvanted nuvaxovid (NVX-CoV2373) novavax vaccine for SARS-CoV-2 could increase vaccine uptake and provide immune protection from viral variants","volume":"28","author":"Parums","year":"2022","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.vaccine.2024.01.034_b0025","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1016\/j.vaccine.2021.07.087","article-title":"Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with advax-SM adjuvant protects against COVID-19 infection","volume":"39","author":"Li","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.034_b0030","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1016\/j.vaccine.2015.09.030","article-title":"Advax\u2122, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety","volume":"33","author":"Petrovsky","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.034_b0035","series-title":"Artificial intelligence in vaccine and drug design","first-page":"131","author":"Thomas","year":"2022"},{"key":"10.1016\/j.vaccine.2024.01.034_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1105655","article-title":"Review: Current trends, challenges, and success stories in adjuvant research","volume":"14","author":"Singleton","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.01.034_b0045","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1016\/j.vaccine.2021.08.050","article-title":"A truncated glycoprotein G vaccine formulated with advax-CpG adjuvant provides protection of mice against genital herpes simplex virus 2 infection","volume":"39","author":"G\u00f6rander","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.034_b0050","doi-asserted-by":"crossref","first-page":"5162","DOI":"10.1016\/j.vaccine.2021.07.037","article-title":"A M2 protein-based universal influenza vaccine containing advax-SM adjuvant provides newborn protection via maternal or neonatal immunization","volume":"39","author":"Sakala","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.034_b0055","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3390\/pathogens10050500","article-title":"Advax-CpG adjuvant provides antigen dose-sparing and enhanced immunogenicity for inactivated poliomyelitis virus vaccines","volume":"10","author":"Honda-Okubo","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2024.01.034_b0060","article-title":"Prefusion RSV F immunization elicits Th2-mediated lung pathology in mice when formulated with a Th2 (but not a Th1\/Th2-balanced) adjuvant despite complete viral protection","volume":"1673","author":"Eichinger","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.01.034_b0065","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1128\/JVI.02980-14","article-title":"Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology","volume":"89","author":"Honda-Okubo","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.01.034_b0070","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3390\/v11030212","article-title":"Efficacy of an adjuvanted Middle East respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas","volume":"11","author":"Adney","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2024.01.034_b0075","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41385-021-00379-6","article-title":"Intrapulmonary vaccination with delta-inulin adjuvant stimulates non-polarised chemotactic signalling and diverse cellular interaction","volume":"14","author":"Ferrell","year":"2021","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2024.01.034_b0080","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/s41385-022-00578-9","article-title":"Mucosal immunization with a delta-inulin adjuvanted recombinant spike vaccine elicits lung-resident immune memory and protects mice against SARS-CoV-2","volume":"15","author":"Stewart","year":"2022","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2024.01.034_b0085","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41541-020-00255-7","article-title":"Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis","volume":"5","author":"Counoupas","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2024.01.034_b0090","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejps.2014.10.008","article-title":"Enhanced pulmonary immunization with aerosolized inactivated influenza vaccine containing delta inulin adjuvant","volume":"66","author":"Murugappan","year":"2015","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.vaccine.2024.01.034_b0095","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jconrel.2018.09.006","article-title":"Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge","volume":"288","author":"Tomar","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2024.01.034_b0100","first-page":"3710","article-title":"Covax-19\/Spikogen\u00ae vaccine based on recombinant spike protein extracellular domain with advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters","volume":"41","author":"Li","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.034_b0105","article-title":"An advax-CpG55.2 adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge","author":"Honda-Okubo","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.034_b0110","doi-asserted-by":"crossref","first-page":"7116","DOI":"10.1016\/j.vaccine.2023.10.018","article-title":"Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants","volume":"41","author":"Honda-Okubo","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.034_b0115","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2027197","article-title":"Strategies to tackle SARS-CoV-2 Mu, a newly classified variant of interest likely to resist currently available COVID-19 vaccines","volume":"18","author":"Hossain","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.01.034_b0120","article-title":"The Mu strain: the last but not least circulating 'variant of interest' potentially affecting the COVID-19 pandemic","author":"Rahimi","year":"2021","journal-title":"Future Virol"},{"key":"10.1016\/j.vaccine.2024.01.034_b0125","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/jmv.27588","article-title":"Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines","volume":"94","author":"Araf","year":"2022","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2024.01.034_b0130","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/s41591-021-01527-y","article-title":"Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis","volume":"27","author":"Choi","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2024.01.034_b0135","doi-asserted-by":"crossref","first-page":"e0159921","DOI":"10.1128\/JVI.01599-21","article-title":"Protective efficacy of gastrointestinal SARS-CoV-2 delivery against intranasal and intratracheal SARS-CoV-2 challenge in rhesus macaques","volume":"96","author":"Yu","year":"2022","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.01.034_b0140","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies","volume":"27","author":"Chen","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2024.01.034_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110218","article-title":"The SARS-CoV-2 lambda variant exhibits enhanced infectivity and immune resistance","volume":"38","author":"Kimura","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2024.01.034_b0150","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2104847118","article-title":"COVID-19 cynomolgus macaque model reflecting human COVID-19 pathological conditions","volume":"118","author":"Urano","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2024.01.034_b0155","doi-asserted-by":"crossref","first-page":"10324","DOI":"10.1128\/JVI.00480-13","article-title":"An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody","volume":"87","author":"Petrovsky","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.01.034_b0160","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/imm.13540","article-title":"Immunogenicity and safety of SpikoGen(R), an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trial","volume":"167","author":"Tabarsi","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2024.01.034_b0165","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1473-3099(23)00363-8","article-title":"Exploring the potential benefits of mucosal COVID-19 vaccines: opportunities and challenges","volume":"23","author":"Croda","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.01.034_b0170","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ijid.2020.09.1484","article-title":"Antibody responses after COVID-19 infection in patients who are mildly symptomatic or asymptomatic in Bangladesh","volume":"101","author":"Shirin","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.01.034_b0175","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41586-021-03925-1","article-title":"Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies","volume":"598","author":"Lempp","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2024.01.034_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104545","article-title":"Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level","volume":"90","author":"Akerman","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2024.01.034_b0185","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/imm.13661","article-title":"Ability of SpikoGen(R), an Advax-CpG adjuvanted recombinant spike protein vaccine, to induce cross-neutralising antibodies against SARS-CoV-2 variants","volume":"170","author":"Honda-Okubo","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2024.01.034_b0190","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.10650","article-title":"Evaluation of waning of SARS-CoV-2 vaccine-induced immunity: A systematic review and meta-analysis","volume":"6","author":"Menegale","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2024.01.034_b0195","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","article-title":"Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections","volume":"26","author":"Long","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2024.01.034_b0200","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.immuni.2020.11.006","article-title":"Germinal center and extrafollicular B cell responses in vaccination, immunity, and autoimmunity","volume":"53","author":"Elsner","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2024.01.034_b0205","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/cyto.a.24285","article-title":"Little to no expression of angiotensin-converting enzyme-2 on most human peripheral blood immune cells but highly expressed on tissue macrophages","volume":"103","author":"Song","year":"2023","journal-title":"Cytometry A"},{"key":"10.1016\/j.vaccine.2024.01.034_b0210","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/infdis\/jiab595","article-title":"T-cell expression of angiotensin-converting enzyme 2 and binding of severe acute respiratory coronavirus 2","volume":"225","author":"Welch","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.01.034_b0215","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/vaccines9010036","article-title":"SARS-CoV-2 spike protein elicits cell signaling in human host cells: Implications for possible consequences of COVID-19 vaccines","volume":"9","author":"Suzuki","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.01.034_b0220","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41422-021-00495-9","article-title":"SARS-CoV-2 spike protein interacts with and activates TLR41","volume":"31","author":"Zhao","year":"2021","journal-title":"Cell Res"},{"key":"10.1016\/j.vaccine.2024.01.034_b0225","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.68563","article-title":"SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-kappaB pathway","volume":"10","author":"Khan","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.vaccine.2024.01.034_b0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011735","article-title":"SARS-CoV-2 suppresses TLR4-induced immunity by dendritic cells via C-type lectin receptor DC-SIGN","volume":"19","author":"van der Donk","year":"2023","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2024.01.034_b0235","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s12015-020-10056-z","article-title":"Human hematopoietic stem, progenitor, and immune cells respond Ex Vivo to SARS-CoV-2 spike protein","volume":"17","author":"Ropa","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/j.vaccine.2024.01.034_b0240","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cmi.2022.09.001","article-title":"Evaluating the efficacy and safety of SpikoGen(R), an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial","volume":"29","author":"Tabarsi","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2024.01.034_b0245","doi-asserted-by":"crossref","first-page":"e13104","DOI":"10.1111\/irv.13104","article-title":"Effectiveness of first and second COVID-19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021-July 2022","volume":"17","author":"Petrie","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2024.01.034_b0250","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMp2215780","article-title":"Bivalent Covid-19 vaccines - A cautionary tale","volume":"388","author":"Offit","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.01.034_b0255","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3390\/microorganisms11041015","article-title":"SARS-CoV-2 related antibody-dependent enhancement phenomena in vitro and in vivo","volume":"11","author":"Nakayama","year":"2023","journal-title":"Microorganisms"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24000343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24000343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:33:45Z","timestamp":1759404825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24000343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0264410X24000343"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.034","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}